Millennium Pharmaceuticals’ chief technology officer, Mike Pavia, is leaving the company after five years to become entrepreneur-in-residence at Oxford Bioscience Partners.
“It’s time to go out and help incubate the next generation of technologies,” Pavia said in an e-mail to ProteoMonitor’s sister publication GenomeWeb. Pavia will remain a consultant to Millennium.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
